nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—kidney cancer—urinary bladder cancer	0.444	1	CtDrD
Erlotinib—EGFR—urinary bladder cancer	0.189	1	CbGaD
Erlotinib—UGT1A1—Etoposide—urinary bladder cancer	0.0176	0.102	CbGbCtD
Erlotinib—ABCB1—Mitomycin—urinary bladder cancer	0.017	0.0987	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—urinary bladder cancer	0.0139	0.0807	CbGbCtD
Erlotinib—ABCG2—Fluorouracil—urinary bladder cancer	0.0116	0.0674	CbGbCtD
Erlotinib—ABCG2—Carboplatin—urinary bladder cancer	0.0116	0.067	CbGbCtD
Erlotinib—ABCG2—Cisplatin—urinary bladder cancer	0.00987	0.0572	CbGbCtD
Erlotinib—ABCG2—Etoposide—urinary bladder cancer	0.0097	0.0562	CbGbCtD
Erlotinib—ALB—Fluorouracil—urinary bladder cancer	0.00801	0.0465	CbGbCtD
Erlotinib—CYP3A4—Thiotepa—urinary bladder cancer	0.00773	0.0448	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—urinary bladder cancer	0.00662	0.0384	CbGbCtD
Erlotinib—ABCG2—Methotrexate—urinary bladder cancer	0.00641	0.0372	CbGbCtD
Erlotinib—CYP2C8—Fluorouracil—urinary bladder cancer	0.00619	0.0359	CbGbCtD
Erlotinib—CYP3A5—Etoposide—urinary bladder cancer	0.00537	0.0312	CbGbCtD
Erlotinib—CYP2C8—Etoposide—urinary bladder cancer	0.00517	0.03	CbGbCtD
Erlotinib—ABCB1—Gemcitabine—urinary bladder cancer	0.0049	0.0284	CbGbCtD
Erlotinib—CYP1A2—Fluorouracil—urinary bladder cancer	0.00479	0.0278	CbGbCtD
Erlotinib—ALB—Methotrexate—urinary bladder cancer	0.00442	0.0256	CbGbCtD
Erlotinib—CYP1A2—Etoposide—urinary bladder cancer	0.004	0.0232	CbGbCtD
Erlotinib—ABCB1—Cisplatin—urinary bladder cancer	0.00356	0.0206	CbGbCtD
Erlotinib—ABCB1—Etoposide—urinary bladder cancer	0.0035	0.0203	CbGbCtD
Erlotinib—ABCB1—Doxorubicin—urinary bladder cancer	0.00239	0.0138	CbGbCtD
Erlotinib—ABCB1—Methotrexate—urinary bladder cancer	0.00231	0.0134	CbGbCtD
Erlotinib—CYP2D6—Doxorubicin—urinary bladder cancer	0.00225	0.013	CbGbCtD
Erlotinib—CYP3A4—Etoposide—urinary bladder cancer	0.0021	0.0122	CbGbCtD
Erlotinib—UGT1A1—urine—urinary bladder cancer	0.00168	0.0379	CbGeAlD
Erlotinib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00143	0.00829	CbGbCtD
Erlotinib—JAK3—prostate gland—urinary bladder cancer	0.00121	0.0273	CbGeAlD
Erlotinib—EPHA6—prostate gland—urinary bladder cancer	0.00121	0.0273	CbGeAlD
Erlotinib—TNK1—prostate gland—urinary bladder cancer	0.00111	0.0251	CbGeAlD
Erlotinib—ABL2—prostate gland—urinary bladder cancer	0.000914	0.0206	CbGeAlD
Erlotinib—EGFR—prostate gland—urinary bladder cancer	0.000892	0.0201	CbGeAlD
Erlotinib—PIP4K2C—prostate gland—urinary bladder cancer	0.000865	0.0195	CbGeAlD
Erlotinib—HIPK4—female reproductive system—urinary bladder cancer	0.000838	0.0189	CbGeAlD
Erlotinib—LTK—female reproductive system—urinary bladder cancer	0.000828	0.0187	CbGeAlD
Erlotinib—ULK3—prostate gland—urinary bladder cancer	0.000826	0.0186	CbGeAlD
Erlotinib—Vandetanib—SRC—urinary bladder cancer	0.000818	0.433	CrCbGaD
Erlotinib—MKNK1—prostate gland—urinary bladder cancer	0.000777	0.0175	CbGeAlD
Erlotinib—TNK1—urethra—urinary bladder cancer	0.000746	0.0168	CbGeAlD
Erlotinib—CYP1A2—urine—urinary bladder cancer	0.000745	0.0168	CbGeAlD
Erlotinib—SLK—prostate gland—urinary bladder cancer	0.000736	0.0166	CbGeAlD
Erlotinib—PIP4K2C—seminal vesicle—urinary bladder cancer	0.000731	0.0165	CbGeAlD
Erlotinib—AURKC—female reproductive system—urinary bladder cancer	0.000715	0.0161	CbGeAlD
Erlotinib—ULK3—seminal vesicle—urinary bladder cancer	0.000698	0.0157	CbGeAlD
Erlotinib—EPHA6—female reproductive system—urinary bladder cancer	0.000662	0.0149	CbGeAlD
Erlotinib—JAK3—female reproductive system—urinary bladder cancer	0.000662	0.0149	CbGeAlD
Erlotinib—STK10—prostate gland—urinary bladder cancer	0.00064	0.0144	CbGeAlD
Erlotinib—SLK—seminal vesicle—urinary bladder cancer	0.000622	0.014	CbGeAlD
Erlotinib—UGT1A1—prostate gland—urinary bladder cancer	0.000604	0.0136	CbGeAlD
Erlotinib—MAP3K19—female reproductive system—urinary bladder cancer	0.000602	0.0136	CbGeAlD
Erlotinib—PIP4K2C—urethra—urinary bladder cancer	0.000579	0.013	CbGeAlD
Erlotinib—MAP2K5—prostate gland—urinary bladder cancer	0.000571	0.0129	CbGeAlD
Erlotinib—ULK3—urethra—urinary bladder cancer	0.000553	0.0124	CbGeAlD
Erlotinib—TNK1—vagina—urinary bladder cancer	0.00055	0.0124	CbGeAlD
Erlotinib—Vandetanib—EGFR—urinary bladder cancer	0.000549	0.291	CrCbGaD
Erlotinib—CYP3A4—urine—urinary bladder cancer	0.000539	0.0121	CbGeAlD
Erlotinib—CYP2D6—urine—urinary bladder cancer	0.000531	0.012	CbGeAlD
Erlotinib—FLT3—female reproductive system—urinary bladder cancer	0.000522	0.0118	CbGeAlD
Erlotinib—Gefitinib—EGFR—urinary bladder cancer	0.000522	0.276	CrCbGaD
Erlotinib—MKNK1—urethra—urinary bladder cancer	0.00052	0.0117	CbGeAlD
Erlotinib—SLK—urethra—urinary bladder cancer	0.000493	0.0111	CbGeAlD
Erlotinib—LTK—lymph node—urinary bladder cancer	0.000485	0.0109	CbGeAlD
Erlotinib—MAP2K5—seminal vesicle—urinary bladder cancer	0.000483	0.0109	CbGeAlD
Erlotinib—PIP4K2C—female reproductive system—urinary bladder cancer	0.000472	0.0106	CbGeAlD
Erlotinib—ORM1—prostate gland—urinary bladder cancer	0.000464	0.0104	CbGeAlD
Erlotinib—ABL2—vagina—urinary bladder cancer	0.000451	0.0102	CbGeAlD
Erlotinib—ULK3—female reproductive system—urinary bladder cancer	0.000451	0.0101	CbGeAlD
Erlotinib—SLCO2B1—prostate gland—urinary bladder cancer	0.000445	0.01	CbGeAlD
Erlotinib—ABL1—prostate gland—urinary bladder cancer	0.000441	0.00993	CbGeAlD
Erlotinib—STK10—renal system—urinary bladder cancer	0.000436	0.00982	CbGeAlD
Erlotinib—PIP4K2C—vagina—urinary bladder cancer	0.000427	0.00961	CbGeAlD
Erlotinib—MKNK1—female reproductive system—urinary bladder cancer	0.000424	0.00955	CbGeAlD
Erlotinib—AURKC—lymph node—urinary bladder cancer	0.000418	0.00942	CbGeAlD
Erlotinib—UGT1A1—renal system—urinary bladder cancer	0.000412	0.00927	CbGeAlD
Erlotinib—ULK3—vagina—urinary bladder cancer	0.000408	0.00918	CbGeAlD
Erlotinib—JAK3—lymph node—urinary bladder cancer	0.000387	0.00873	CbGeAlD
Erlotinib—MKNK1—vagina—urinary bladder cancer	0.000384	0.00864	CbGeAlD
Erlotinib—MAP2K5—urethra—urinary bladder cancer	0.000383	0.00862	CbGeAlD
Erlotinib—CYP1B1—prostate gland—urinary bladder cancer	0.000373	0.00841	CbGeAlD
Erlotinib—ABL1—seminal vesicle—urinary bladder cancer	0.000373	0.0084	CbGeAlD
Erlotinib—SLK—vagina—urinary bladder cancer	0.000363	0.00818	CbGeAlD
Erlotinib—TNK1—lymph node—urinary bladder cancer	0.000356	0.00801	CbGeAlD
Erlotinib—STK10—female reproductive system—urinary bladder cancer	0.000349	0.00787	CbGeAlD
Erlotinib—ABL1—Idarubicin—Valrubicin—urinary bladder cancer	0.000339	0.166	CbGdCrCtD
Erlotinib—ABL1—Doxorubicin—Valrubicin—urinary bladder cancer	0.000339	0.166	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Valrubicin—urinary bladder cancer	0.000339	0.166	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Valrubicin—urinary bladder cancer	0.000339	0.166	CbGdCrCtD
Erlotinib—STK10—vagina—urinary bladder cancer	0.000316	0.00711	CbGeAlD
Erlotinib—ABL1—smooth muscle tissue—urinary bladder cancer	0.000312	0.00703	CbGeAlD
Erlotinib—MAP2K5—female reproductive system—urinary bladder cancer	0.000312	0.00702	CbGeAlD
Erlotinib—FLT3—lymph node—urinary bladder cancer	0.000306	0.00688	CbGeAlD
Erlotinib—SLCO2B1—renal system—urinary bladder cancer	0.000303	0.00683	CbGeAlD
Erlotinib—ABL1—renal system—urinary bladder cancer	0.0003	0.00677	CbGeAlD
Erlotinib—ABL1—urethra—urinary bladder cancer	0.000295	0.00665	CbGeAlD
Erlotinib—ABL2—lymph node—urinary bladder cancer	0.000292	0.00657	CbGeAlD
Erlotinib—EGFR—lymph node—urinary bladder cancer	0.000285	0.00641	CbGeAlD
Erlotinib—MAP2K5—vagina—urinary bladder cancer	0.000282	0.00635	CbGeAlD
Erlotinib—ABCG2—prostate gland—urinary bladder cancer	0.000278	0.00626	CbGeAlD
Erlotinib—PIP4K2C—lymph node—urinary bladder cancer	0.000276	0.00622	CbGeAlD
Erlotinib—CYP1B1—smooth muscle tissue—urinary bladder cancer	0.000264	0.00595	CbGeAlD
Erlotinib—ULK3—lymph node—urinary bladder cancer	0.000264	0.00594	CbGeAlD
Erlotinib—CYP3A5—prostate gland—urinary bladder cancer	0.000258	0.00581	CbGeAlD
Erlotinib—CYP1B1—renal system—urinary bladder cancer	0.000254	0.00573	CbGeAlD
Erlotinib—ORM1—female reproductive system—urinary bladder cancer	0.000253	0.0057	CbGeAlD
Erlotinib—MKNK1—lymph node—urinary bladder cancer	0.000248	0.00559	CbGeAlD
Erlotinib—SLCO2B1—female reproductive system—urinary bladder cancer	0.000243	0.00547	CbGeAlD
Erlotinib—ABL1—female reproductive system—urinary bladder cancer	0.000241	0.00542	CbGeAlD
Erlotinib—ABCG2—seminal vesicle—urinary bladder cancer	0.000235	0.00529	CbGeAlD
Erlotinib—SLK—lymph node—urinary bladder cancer	0.000235	0.00529	CbGeAlD
Erlotinib—ABL1—vagina—urinary bladder cancer	0.000218	0.0049	CbGeAlD
Erlotinib—STK10—lymph node—urinary bladder cancer	0.000204	0.0046	CbGeAlD
Erlotinib—CYP1B1—female reproductive system—urinary bladder cancer	0.000204	0.00459	CbGeAlD
Erlotinib—CYP2C8—renal system—urinary bladder cancer	0.000195	0.00439	CbGeAlD
Erlotinib—CYP1A1—epithelium—urinary bladder cancer	0.000194	0.00437	CbGeAlD
Erlotinib—ABCG2—urethra—urinary bladder cancer	0.000186	0.00419	CbGeAlD
Erlotinib—MAP2K5—lymph node—urinary bladder cancer	0.000182	0.00411	CbGeAlD
Erlotinib—CYP1A2—renal system—urinary bladder cancer	0.000182	0.00411	CbGeAlD
Erlotinib—CYP1A1—renal system—urinary bladder cancer	0.00018	0.00405	CbGeAlD
Erlotinib—CYP1A1—urethra—urinary bladder cancer	0.000177	0.00398	CbGeAlD
Erlotinib—CYP3A5—renal system—urinary bladder cancer	0.000176	0.00396	CbGeAlD
Erlotinib—CYP2C8—female reproductive system—urinary bladder cancer	0.000156	0.00351	CbGeAlD
Erlotinib—ORM1—lymph node—urinary bladder cancer	0.000148	0.00334	CbGeAlD
Erlotinib—CYP1A1—female reproductive system—urinary bladder cancer	0.000144	0.00324	CbGeAlD
Erlotinib—SLCO2B1—lymph node—urinary bladder cancer	0.000142	0.0032	CbGeAlD
Erlotinib—CYP2C8—vagina—urinary bladder cancer	0.000141	0.00318	CbGeAlD
Erlotinib—ABL1—lymph node—urinary bladder cancer	0.000141	0.00317	CbGeAlD
Erlotinib—ABCG2—vagina—urinary bladder cancer	0.000137	0.00309	CbGeAlD
Erlotinib—ABCB1—prostate gland—urinary bladder cancer	0.000137	0.00309	CbGeAlD
Erlotinib—CYP3A4—renal system—urinary bladder cancer	0.000132	0.00297	CbGeAlD
Erlotinib—CYP1A1—vagina—urinary bladder cancer	0.00013	0.00293	CbGeAlD
Erlotinib—ALB—lymph node—urinary bladder cancer	0.00013	0.00293	CbGeAlD
Erlotinib—CYP2D6—renal system—urinary bladder cancer	0.00013	0.00292	CbGeAlD
Erlotinib—CYP3A5—vagina—urinary bladder cancer	0.000127	0.00287	CbGeAlD
Erlotinib—CYP1B1—lymph node—urinary bladder cancer	0.000119	0.00268	CbGeAlD
Erlotinib—ABL1—Doxorubicin—Epirubicin—urinary bladder cancer	0.000118	0.0579	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Epirubicin—urinary bladder cancer	0.000118	0.0579	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Epirubicin—urinary bladder cancer	0.000118	0.0579	CbGdCrCtD
Erlotinib—ABCB1—seminal vesicle—urinary bladder cancer	0.000116	0.00261	CbGeAlD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000109	0.0536	CbGdCrCtD
Erlotinib—ABL1—Epirubicin—Doxorubicin—urinary bladder cancer	0.000109	0.0536	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Doxorubicin—urinary bladder cancer	0.000109	0.0536	CbGdCrCtD
Erlotinib—CYP3A4—female reproductive system—urinary bladder cancer	0.000106	0.00238	CbGeAlD
Erlotinib—CYP2D6—female reproductive system—urinary bladder cancer	0.000104	0.00234	CbGeAlD
Erlotinib—ABCB1—epithelium—urinary bladder cancer	0.000101	0.00227	CbGeAlD
Erlotinib—ABCB1—renal system—urinary bladder cancer	9.34e-05	0.0021	CbGeAlD
Erlotinib—ABCB1—urethra—urinary bladder cancer	9.18e-05	0.00207	CbGeAlD
Erlotinib—ABCG2—lymph node—urinary bladder cancer	8.88e-05	0.002	CbGeAlD
Erlotinib—CYP1A1—lymph node—urinary bladder cancer	8.43e-05	0.0019	CbGeAlD
Erlotinib—ABCB1—female reproductive system—urinary bladder cancer	7.48e-05	0.00169	CbGeAlD
Erlotinib—ABCB1—vagina—urinary bladder cancer	6.77e-05	0.00152	CbGeAlD
Erlotinib—Dehydration—Doxorubicin—urinary bladder cancer	6.04e-05	0.000723	CcSEcCtD
Erlotinib—Thrombocytopenia—Etoposide—urinary bladder cancer	6.02e-05	0.000721	CcSEcCtD
Erlotinib—Dyspnoea—Cisplatin—urinary bladder cancer	5.99e-05	0.000717	CcSEcCtD
Erlotinib—Skin disorder—Etoposide—urinary bladder cancer	5.97e-05	0.000716	CcSEcCtD
Erlotinib—Dry skin—Doxorubicin—urinary bladder cancer	5.95e-05	0.000713	CcSEcCtD
Erlotinib—Pancreatitis—Epirubicin—urinary bladder cancer	5.94e-05	0.000712	CcSEcCtD
Erlotinib—Hypokalaemia—Doxorubicin—urinary bladder cancer	5.91e-05	0.000708	CcSEcCtD
Erlotinib—Anorexia—Etoposide—urinary bladder cancer	5.86e-05	0.000702	CcSEcCtD
Erlotinib—Diarrhoea—Thiotepa—urinary bladder cancer	5.86e-05	0.000702	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	5.84e-05	0.0007	CcSEcCtD
Erlotinib—Decreased appetite—Cisplatin—urinary bladder cancer	5.84e-05	0.000699	CcSEcCtD
Erlotinib—Pneumonia—Methotrexate—urinary bladder cancer	5.81e-05	0.000696	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	5.8e-05	0.000694	CcSEcCtD
Erlotinib—Infestation NOS—Methotrexate—urinary bladder cancer	5.78e-05	0.000692	CcSEcCtD
Erlotinib—Infestation—Methotrexate—urinary bladder cancer	5.78e-05	0.000692	CcSEcCtD
Erlotinib—Depression—Methotrexate—urinary bladder cancer	5.76e-05	0.00069	CcSEcCtD
Erlotinib—Gastritis—Doxorubicin—urinary bladder cancer	5.74e-05	0.000688	CcSEcCtD
Erlotinib—Pain—Cisplatin—urinary bladder cancer	5.74e-05	0.000688	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	5.73e-05	0.000686	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	5.72e-05	0.000686	CcSEcCtD
Erlotinib—Body temperature increased—Gemcitabine—urinary bladder cancer	5.69e-05	0.000682	CcSEcCtD
Erlotinib—Renal failure—Methotrexate—urinary bladder cancer	5.68e-05	0.00068	CcSEcCtD
Erlotinib—Neutropenia—Epirubicin—urinary bladder cancer	5.67e-05	0.000679	CcSEcCtD
Erlotinib—Dizziness—Thiotepa—urinary bladder cancer	5.66e-05	0.000678	CcSEcCtD
Erlotinib—Stomatitis—Methotrexate—urinary bladder cancer	5.63e-05	0.000674	CcSEcCtD
Erlotinib—Conjunctivitis—Methotrexate—urinary bladder cancer	5.61e-05	0.000673	CcSEcCtD
Erlotinib—Dysphagia—Doxorubicin—urinary bladder cancer	5.61e-05	0.000672	CcSEcCtD
Erlotinib—Body temperature increased—Fluorouracil—urinary bladder cancer	5.6e-05	0.000671	CcSEcCtD
Erlotinib—Pancreatitis—Doxorubicin—urinary bladder cancer	5.5e-05	0.000659	CcSEcCtD
Erlotinib—Weight decreased—Epirubicin—urinary bladder cancer	5.48e-05	0.000657	CcSEcCtD
Erlotinib—Dyspnoea—Etoposide—urinary bladder cancer	5.48e-05	0.000657	CcSEcCtD
Erlotinib—Hepatobiliary disease—Methotrexate—urinary bladder cancer	5.46e-05	0.000654	CcSEcCtD
Erlotinib—Epistaxis—Methotrexate—urinary bladder cancer	5.45e-05	0.000653	CcSEcCtD
Erlotinib—Vomiting—Thiotepa—urinary bladder cancer	5.44e-05	0.000652	CcSEcCtD
Erlotinib—Pneumonia—Epirubicin—urinary bladder cancer	5.44e-05	0.000651	CcSEcCtD
Erlotinib—Infestation NOS—Epirubicin—urinary bladder cancer	5.41e-05	0.000648	CcSEcCtD
Erlotinib—Infestation—Epirubicin—urinary bladder cancer	5.41e-05	0.000648	CcSEcCtD
Erlotinib—Rash—Thiotepa—urinary bladder cancer	5.4e-05	0.000647	CcSEcCtD
Erlotinib—Dermatitis—Thiotepa—urinary bladder cancer	5.39e-05	0.000646	CcSEcCtD
Erlotinib—Headache—Thiotepa—urinary bladder cancer	5.36e-05	0.000643	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	5.36e-05	0.000642	CcSEcCtD
Erlotinib—Decreased appetite—Etoposide—urinary bladder cancer	5.35e-05	0.00064	CcSEcCtD
Erlotinib—Renal failure—Epirubicin—urinary bladder cancer	5.31e-05	0.000637	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	5.31e-05	0.000636	CcSEcCtD
Erlotinib—Body temperature increased—Cisplatin—urinary bladder cancer	5.31e-05	0.000636	CcSEcCtD
Erlotinib—Fatigue—Etoposide—urinary bladder cancer	5.3e-05	0.000635	CcSEcCtD
Erlotinib—Neuropathy peripheral—Epirubicin—urinary bladder cancer	5.3e-05	0.000635	CcSEcCtD
Erlotinib—Stomatitis—Epirubicin—urinary bladder cancer	5.27e-05	0.000631	CcSEcCtD
Erlotinib—Constipation—Etoposide—urinary bladder cancer	5.26e-05	0.00063	CcSEcCtD
Erlotinib—Pain—Etoposide—urinary bladder cancer	5.26e-05	0.00063	CcSEcCtD
Erlotinib—Conjunctivitis—Epirubicin—urinary bladder cancer	5.25e-05	0.000629	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—urinary bladder cancer	5.25e-05	0.000628	CcSEcCtD
Erlotinib—Haemoglobin—Methotrexate—urinary bladder cancer	5.21e-05	0.000624	CcSEcCtD
Erlotinib—Haemorrhage—Methotrexate—urinary bladder cancer	5.19e-05	0.000621	CcSEcCtD
Erlotinib—Hepatitis—Methotrexate—urinary bladder cancer	5.19e-05	0.000621	CcSEcCtD
Erlotinib—Asthenia—Gemcitabine—urinary bladder cancer	5.17e-05	0.000619	CcSEcCtD
Erlotinib—Urinary tract disorder—Methotrexate—urinary bladder cancer	5.12e-05	0.000613	CcSEcCtD
Erlotinib—Hepatobiliary disease—Epirubicin—urinary bladder cancer	5.11e-05	0.000612	CcSEcCtD
Erlotinib—Epistaxis—Epirubicin—urinary bladder cancer	5.1e-05	0.000611	CcSEcCtD
Erlotinib—Pruritus—Gemcitabine—urinary bladder cancer	5.1e-05	0.00061	CcSEcCtD
Erlotinib—Nausea—Thiotepa—urinary bladder cancer	5.09e-05	0.000609	CcSEcCtD
Erlotinib—Urethral disorder—Methotrexate—urinary bladder cancer	5.08e-05	0.000609	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—urinary bladder cancer	5.08e-05	0.000608	CcSEcCtD
Erlotinib—Pneumonia—Doxorubicin—urinary bladder cancer	5.03e-05	0.000603	CcSEcCtD
Erlotinib—Gastrointestinal pain—Etoposide—urinary bladder cancer	5.03e-05	0.000602	CcSEcCtD
Erlotinib—Pruritus—Fluorouracil—urinary bladder cancer	5.01e-05	0.0006	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—urinary bladder cancer	5e-05	0.000599	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—urinary bladder cancer	5e-05	0.000599	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	4.96e-05	0.000594	CcSEcCtD
Erlotinib—Diarrhoea—Gemcitabine—urinary bladder cancer	4.93e-05	0.00059	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—urinary bladder cancer	4.92e-05	0.000589	CcSEcCtD
Erlotinib—Erythema multiforme—Methotrexate—urinary bladder cancer	4.9e-05	0.000587	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	4.9e-05	0.000587	CcSEcCtD
Erlotinib—Haemoglobin—Epirubicin—urinary bladder cancer	4.88e-05	0.000584	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—urinary bladder cancer	4.88e-05	0.000584	CcSEcCtD
Erlotinib—Abdominal pain—Etoposide—urinary bladder cancer	4.86e-05	0.000582	CcSEcCtD
Erlotinib—Body temperature increased—Etoposide—urinary bladder cancer	4.86e-05	0.000582	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—urinary bladder cancer	4.86e-05	0.000582	CcSEcCtD
Erlotinib—Hepatitis—Epirubicin—urinary bladder cancer	4.85e-05	0.000581	CcSEcCtD
Erlotinib—Haemorrhage—Epirubicin—urinary bladder cancer	4.85e-05	0.000581	CcSEcCtD
Erlotinib—Eye disorder—Methotrexate—urinary bladder cancer	4.85e-05	0.00058	CcSEcCtD
Erlotinib—Diarrhoea—Fluorouracil—urinary bladder cancer	4.85e-05	0.00058	CcSEcCtD
Erlotinib—Asthenia—Cisplatin—urinary bladder cancer	4.82e-05	0.000577	CcSEcCtD
Erlotinib—Urinary tract disorder—Epirubicin—urinary bladder cancer	4.79e-05	0.000574	CcSEcCtD
Erlotinib—Connective tissue disorder—Epirubicin—urinary bladder cancer	4.77e-05	0.000571	CcSEcCtD
Erlotinib—Urethral disorder—Epirubicin—urinary bladder cancer	4.76e-05	0.00057	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	4.73e-05	0.000567	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—urinary bladder cancer	4.72e-05	0.000565	CcSEcCtD
Erlotinib—Dizziness—Fluorouracil—urinary bladder cancer	4.68e-05	0.000561	CcSEcCtD
Erlotinib—Mediastinal disorder—Methotrexate—urinary bladder cancer	4.67e-05	0.00056	CcSEcCtD
Erlotinib—Chills—Methotrexate—urinary bladder cancer	4.65e-05	0.000557	CcSEcCtD
Erlotinib—Diarrhoea—Cisplatin—urinary bladder cancer	4.59e-05	0.00055	CcSEcCtD
Erlotinib—Erythema multiforme—Epirubicin—urinary bladder cancer	4.59e-05	0.00055	CcSEcCtD
Erlotinib—Alopecia—Methotrexate—urinary bladder cancer	4.58e-05	0.000549	CcSEcCtD
Erlotinib—Vomiting—Gemcitabine—urinary bladder cancer	4.58e-05	0.000549	CcSEcCtD
Erlotinib—Mental disorder—Methotrexate—urinary bladder cancer	4.54e-05	0.000544	CcSEcCtD
Erlotinib—Rash—Gemcitabine—urinary bladder cancer	4.54e-05	0.000544	CcSEcCtD
Erlotinib—Dermatitis—Gemcitabine—urinary bladder cancer	4.54e-05	0.000544	CcSEcCtD
Erlotinib—Eye disorder—Epirubicin—urinary bladder cancer	4.53e-05	0.000543	CcSEcCtD
Erlotinib—Erythema—Methotrexate—urinary bladder cancer	4.51e-05	0.000541	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—urinary bladder cancer	4.51e-05	0.000541	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—urinary bladder cancer	4.51e-05	0.000541	CcSEcCtD
Erlotinib—Headache—Gemcitabine—urinary bladder cancer	4.51e-05	0.000541	CcSEcCtD
Erlotinib—Vomiting—Fluorouracil—urinary bladder cancer	4.5e-05	0.000539	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—urinary bladder cancer	4.49e-05	0.000538	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—urinary bladder cancer	4.49e-05	0.000538	CcSEcCtD
Erlotinib—Rash—Fluorouracil—urinary bladder cancer	4.47e-05	0.000535	CcSEcCtD
Erlotinib—Dermatitis—Fluorouracil—urinary bladder cancer	4.46e-05	0.000534	CcSEcCtD
Erlotinib—Headache—Fluorouracil—urinary bladder cancer	4.44e-05	0.000531	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	4.43e-05	0.000531	CcSEcCtD
Erlotinib—Asthenia—Etoposide—urinary bladder cancer	4.41e-05	0.000529	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	4.41e-05	0.000529	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—urinary bladder cancer	4.4e-05	0.000527	CcSEcCtD
Erlotinib—ABCB1—lymph node—urinary bladder cancer	4.38e-05	0.000986	CbGeAlD
Erlotinib—Mediastinal disorder—Epirubicin—urinary bladder cancer	4.37e-05	0.000524	CcSEcCtD
Erlotinib—Back pain—Methotrexate—urinary bladder cancer	4.37e-05	0.000523	CcSEcCtD
Erlotinib—Chills—Epirubicin—urinary bladder cancer	4.35e-05	0.000522	CcSEcCtD
Erlotinib—Pruritus—Etoposide—urinary bladder cancer	4.35e-05	0.000521	CcSEcCtD
Erlotinib—Arrhythmia—Epirubicin—urinary bladder cancer	4.34e-05	0.000519	CcSEcCtD
Erlotinib—Alopecia—Epirubicin—urinary bladder cancer	4.29e-05	0.000514	CcSEcCtD
Erlotinib—Nausea—Gemcitabine—urinary bladder cancer	4.28e-05	0.000512	CcSEcCtD
Erlotinib—Vomiting—Cisplatin—urinary bladder cancer	4.27e-05	0.000511	CcSEcCtD
Erlotinib—Mental disorder—Epirubicin—urinary bladder cancer	4.25e-05	0.000509	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—urinary bladder cancer	4.25e-05	0.000509	CcSEcCtD
Erlotinib—Rash—Cisplatin—urinary bladder cancer	4.23e-05	0.000507	CcSEcCtD
Erlotinib—Dermatitis—Cisplatin—urinary bladder cancer	4.23e-05	0.000507	CcSEcCtD
Erlotinib—Erythema—Epirubicin—urinary bladder cancer	4.22e-05	0.000506	CcSEcCtD
Erlotinib—Malnutrition—Epirubicin—urinary bladder cancer	4.22e-05	0.000506	CcSEcCtD
Erlotinib—Diarrhoea—Etoposide—urinary bladder cancer	4.21e-05	0.000504	CcSEcCtD
Erlotinib—Nausea—Fluorouracil—urinary bladder cancer	4.21e-05	0.000504	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—urinary bladder cancer	4.2e-05	0.000503	CcSEcCtD
Erlotinib—Flatulence—Epirubicin—urinary bladder cancer	4.16e-05	0.000499	CcSEcCtD
Erlotinib—Back pain—Epirubicin—urinary bladder cancer	4.09e-05	0.000489	CcSEcCtD
Erlotinib—Dizziness—Etoposide—urinary bladder cancer	4.07e-05	0.000487	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	4.05e-05	0.000485	CcSEcCtD
Erlotinib—Chills—Doxorubicin—urinary bladder cancer	4.03e-05	0.000483	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—urinary bladder cancer	4.01e-05	0.00048	CcSEcCtD
Erlotinib—Nausea—Cisplatin—urinary bladder cancer	3.99e-05	0.000478	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—urinary bladder cancer	3.97e-05	0.000475	CcSEcCtD
Erlotinib—Cough—Methotrexate—urinary bladder cancer	3.94e-05	0.000472	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—urinary bladder cancer	3.93e-05	0.000471	CcSEcCtD
Erlotinib—Vomiting—Etoposide—urinary bladder cancer	3.91e-05	0.000468	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—urinary bladder cancer	3.91e-05	0.000468	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—urinary bladder cancer	3.91e-05	0.000468	CcSEcCtD
Erlotinib—Rash—Etoposide—urinary bladder cancer	3.88e-05	0.000465	CcSEcCtD
Erlotinib—Dermatitis—Etoposide—urinary bladder cancer	3.87e-05	0.000464	CcSEcCtD
Erlotinib—Headache—Etoposide—urinary bladder cancer	3.85e-05	0.000462	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—urinary bladder cancer	3.85e-05	0.000461	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—urinary bladder cancer	3.84e-05	0.00046	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—urinary bladder cancer	3.84e-05	0.00046	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—urinary bladder cancer	3.84e-05	0.00046	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	3.82e-05	0.000457	CcSEcCtD
Erlotinib—Syncope—Epirubicin—urinary bladder cancer	3.79e-05	0.000454	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—urinary bladder cancer	3.78e-05	0.000453	CcSEcCtD
Erlotinib—Loss of consciousness—Epirubicin—urinary bladder cancer	3.71e-05	0.000445	CcSEcCtD
Erlotinib—Cough—Epirubicin—urinary bladder cancer	3.69e-05	0.000442	CcSEcCtD
Erlotinib—Infection—Methotrexate—urinary bladder cancer	3.66e-05	0.000438	CcSEcCtD
Erlotinib—Nausea—Etoposide—urinary bladder cancer	3.65e-05	0.000438	CcSEcCtD
Erlotinib—Nervous system disorder—Methotrexate—urinary bladder cancer	3.61e-05	0.000433	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.61e-05	0.000432	CcSEcCtD
Erlotinib—Chest pain—Epirubicin—urinary bladder cancer	3.6e-05	0.000431	CcSEcCtD
Erlotinib—Arthralgia—Epirubicin—urinary bladder cancer	3.6e-05	0.000431	CcSEcCtD
Erlotinib—Myalgia—Epirubicin—urinary bladder cancer	3.6e-05	0.000431	CcSEcCtD
Erlotinib—Anxiety—Epirubicin—urinary bladder cancer	3.58e-05	0.000429	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—urinary bladder cancer	3.58e-05	0.000429	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	3.57e-05	0.000428	CcSEcCtD
Erlotinib—Anorexia—Methotrexate—urinary bladder cancer	3.51e-05	0.000421	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—urinary bladder cancer	3.51e-05	0.00042	CcSEcCtD
Erlotinib—Oedema—Epirubicin—urinary bladder cancer	3.45e-05	0.000413	CcSEcCtD
Erlotinib—Loss of consciousness—Doxorubicin—urinary bladder cancer	3.44e-05	0.000412	CcSEcCtD
Erlotinib—Infection—Epirubicin—urinary bladder cancer	3.43e-05	0.00041	CcSEcCtD
Erlotinib—Cough—Doxorubicin—urinary bladder cancer	3.41e-05	0.000409	CcSEcCtD
Erlotinib—Shock—Epirubicin—urinary bladder cancer	3.39e-05	0.000406	CcSEcCtD
Erlotinib—Nervous system disorder—Epirubicin—urinary bladder cancer	3.38e-05	0.000405	CcSEcCtD
Erlotinib—Thrombocytopenia—Epirubicin—urinary bladder cancer	3.38e-05	0.000404	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	3.36e-05	0.000402	CcSEcCtD
Erlotinib—Skin disorder—Epirubicin—urinary bladder cancer	3.35e-05	0.000401	CcSEcCtD
Erlotinib—Insomnia—Methotrexate—urinary bladder cancer	3.33e-05	0.000399	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—urinary bladder cancer	3.33e-05	0.000399	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—urinary bladder cancer	3.33e-05	0.000399	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—urinary bladder cancer	3.33e-05	0.000399	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—urinary bladder cancer	3.32e-05	0.000397	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	3.3e-05	0.000396	CcSEcCtD
Erlotinib—Anorexia—Epirubicin—urinary bladder cancer	3.29e-05	0.000394	CcSEcCtD
Erlotinib—Dyspnoea—Methotrexate—urinary bladder cancer	3.28e-05	0.000393	CcSEcCtD
Erlotinib—Dyspepsia—Methotrexate—urinary bladder cancer	3.24e-05	0.000388	CcSEcCtD
Erlotinib—Decreased appetite—Methotrexate—urinary bladder cancer	3.2e-05	0.000384	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—urinary bladder cancer	3.19e-05	0.000382	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	3.18e-05	0.000381	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—urinary bladder cancer	3.18e-05	0.00038	CcSEcCtD
Erlotinib—Infection—Doxorubicin—urinary bladder cancer	3.17e-05	0.00038	CcSEcCtD
Erlotinib—Pain—Methotrexate—urinary bladder cancer	3.15e-05	0.000377	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	3.14e-05	0.000376	CcSEcCtD
Erlotinib—Shock—Doxorubicin—urinary bladder cancer	3.14e-05	0.000376	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—urinary bladder cancer	3.13e-05	0.000375	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	3.12e-05	0.000374	CcSEcCtD
Erlotinib—Insomnia—Epirubicin—urinary bladder cancer	3.12e-05	0.000374	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—urinary bladder cancer	3.1e-05	0.000371	CcSEcCtD
Erlotinib—Dyspnoea—Epirubicin—urinary bladder cancer	3.07e-05	0.000368	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—urinary bladder cancer	3.04e-05	0.000364	CcSEcCtD
Erlotinib—Dyspepsia—Epirubicin—urinary bladder cancer	3.03e-05	0.000364	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	3.01e-05	0.000361	CcSEcCtD
Erlotinib—Decreased appetite—Epirubicin—urinary bladder cancer	3e-05	0.000359	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.98e-05	0.000357	CcSEcCtD
Erlotinib—Fatigue—Epirubicin—urinary bladder cancer	2.97e-05	0.000356	CcSEcCtD
Erlotinib—Constipation—Epirubicin—urinary bladder cancer	2.95e-05	0.000353	CcSEcCtD
Erlotinib—Pain—Epirubicin—urinary bladder cancer	2.95e-05	0.000353	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—urinary bladder cancer	2.91e-05	0.000349	CcSEcCtD
Erlotinib—Body temperature increased—Methotrexate—urinary bladder cancer	2.91e-05	0.000349	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.91e-05	0.000348	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—urinary bladder cancer	2.89e-05	0.000346	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—urinary bladder cancer	2.84e-05	0.000341	CcSEcCtD
Erlotinib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.82e-05	0.000338	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—urinary bladder cancer	2.81e-05	0.000336	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—urinary bladder cancer	2.77e-05	0.000332	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.75e-05	0.00033	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—urinary bladder cancer	2.75e-05	0.000329	CcSEcCtD
Erlotinib—Pain—Doxorubicin—urinary bladder cancer	2.73e-05	0.000327	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—urinary bladder cancer	2.73e-05	0.000327	CcSEcCtD
Erlotinib—Abdominal pain—Epirubicin—urinary bladder cancer	2.73e-05	0.000326	CcSEcCtD
Erlotinib—Body temperature increased—Epirubicin—urinary bladder cancer	2.73e-05	0.000326	CcSEcCtD
Erlotinib—Asthenia—Methotrexate—urinary bladder cancer	2.64e-05	0.000317	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.61e-05	0.000312	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—urinary bladder cancer	2.61e-05	0.000312	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—urinary bladder cancer	2.52e-05	0.000302	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—urinary bladder cancer	2.52e-05	0.000302	CcSEcCtD
Erlotinib—Diarrhoea—Methotrexate—urinary bladder cancer	2.52e-05	0.000302	CcSEcCtD
Erlotinib—Asthenia—Epirubicin—urinary bladder cancer	2.47e-05	0.000296	CcSEcCtD
Erlotinib—Pruritus—Epirubicin—urinary bladder cancer	2.44e-05	0.000292	CcSEcCtD
Erlotinib—Dizziness—Methotrexate—urinary bladder cancer	2.44e-05	0.000292	CcSEcCtD
Erlotinib—Diarrhoea—Epirubicin—urinary bladder cancer	2.36e-05	0.000283	CcSEcCtD
Erlotinib—Vomiting—Methotrexate—urinary bladder cancer	2.34e-05	0.000281	CcSEcCtD
Erlotinib—Rash—Methotrexate—urinary bladder cancer	2.32e-05	0.000278	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—urinary bladder cancer	2.32e-05	0.000278	CcSEcCtD
Erlotinib—Headache—Methotrexate—urinary bladder cancer	2.31e-05	0.000276	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—urinary bladder cancer	2.29e-05	0.000274	CcSEcCtD
Erlotinib—Dizziness—Epirubicin—urinary bladder cancer	2.28e-05	0.000273	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—urinary bladder cancer	2.26e-05	0.00027	CcSEcCtD
Erlotinib—Vomiting—Epirubicin—urinary bladder cancer	2.19e-05	0.000263	CcSEcCtD
Erlotinib—Nausea—Methotrexate—urinary bladder cancer	2.19e-05	0.000262	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—urinary bladder cancer	2.18e-05	0.000261	CcSEcCtD
Erlotinib—Rash—Epirubicin—urinary bladder cancer	2.17e-05	0.00026	CcSEcCtD
Erlotinib—Dermatitis—Epirubicin—urinary bladder cancer	2.17e-05	0.00026	CcSEcCtD
Erlotinib—Headache—Epirubicin—urinary bladder cancer	2.16e-05	0.000259	CcSEcCtD
Erlotinib—Dizziness—Doxorubicin—urinary bladder cancer	2.11e-05	0.000253	CcSEcCtD
Erlotinib—Nausea—Epirubicin—urinary bladder cancer	2.05e-05	0.000245	CcSEcCtD
Erlotinib—Vomiting—Doxorubicin—urinary bladder cancer	2.03e-05	0.000243	CcSEcCtD
Erlotinib—Rash—Doxorubicin—urinary bladder cancer	2.01e-05	0.000241	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—urinary bladder cancer	2.01e-05	0.000241	CcSEcCtD
Erlotinib—Headache—Doxorubicin—urinary bladder cancer	2e-05	0.000239	CcSEcCtD
Erlotinib—Nausea—Doxorubicin—urinary bladder cancer	1.89e-05	0.000227	CcSEcCtD
Erlotinib—ABCG2—Metabolism—GPX1—urinary bladder cancer	3.44e-06	5.48e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.44e-06	5.48e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.43e-06	5.46e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CREBBP—urinary bladder cancer	3.43e-06	5.46e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—RHOA—urinary bladder cancer	3.41e-06	5.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDH1—urinary bladder cancer	3.4e-06	5.42e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—RRM2—urinary bladder cancer	3.4e-06	5.41e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—RHOA—urinary bladder cancer	3.4e-06	5.4e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ERCC2—urinary bladder cancer	3.38e-06	5.38e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NQO1—urinary bladder cancer	3.36e-06	5.35e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ERBB2—urinary bladder cancer	3.36e-06	5.35e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SRC—urinary bladder cancer	3.36e-06	5.34e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.35e-06	5.34e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.34e-06	5.31e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CXCL8—urinary bladder cancer	3.28e-06	5.22e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—urinary bladder cancer	3.28e-06	5.21e-05	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.26e-06	5.19e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KRAS—urinary bladder cancer	3.23e-06	5.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NCOR1—urinary bladder cancer	3.22e-06	5.13e-05	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HRAS—urinary bladder cancer	3.21e-06	5.11e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.2e-06	5.1e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MTHFR—urinary bladder cancer	3.18e-06	5.06e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NQO1—urinary bladder cancer	3.18e-06	5.05e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CREBBP—urinary bladder cancer	3.17e-06	5.04e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—HPGDS—urinary bladder cancer	3.15e-06	5.01e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ENO2—urinary bladder cancer	3.15e-06	5.01e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NAT2—urinary bladder cancer	3.14e-06	5e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL2—urinary bladder cancer	3.14e-06	4.99e-05	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRAS—urinary bladder cancer	3.13e-06	4.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HRAS—urinary bladder cancer	3.11e-06	4.95e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KRAS—urinary bladder cancer	3.1e-06	4.94e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.08e-06	4.9e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CCND1—urinary bladder cancer	3.06e-06	4.87e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTT1—urinary bladder cancer	3.05e-06	4.86e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL2—urinary bladder cancer	3.05e-06	4.85e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PPARG—urinary bladder cancer	3.04e-06	4.83e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MYC—urinary bladder cancer	3.01e-06	4.79e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CXCL8—urinary bladder cancer	2.98e-06	4.74e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MMP9—urinary bladder cancer	2.97e-06	4.72e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.97e-06	4.72e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.97e-06	4.72e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CDKN1A—urinary bladder cancer	2.96e-06	4.71e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PTEN—urinary bladder cancer	2.95e-06	4.7e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EGFR—urinary bladder cancer	2.94e-06	4.68e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	2.92e-06	4.64e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NQO1—urinary bladder cancer	2.91e-06	4.63e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NQO1—urinary bladder cancer	2.9e-06	4.61e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.88e-06	4.58e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CDKN1A—urinary bladder cancer	2.87e-06	4.57e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB2—urinary bladder cancer	2.87e-06	4.57e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—PTEN—urinary bladder cancer	2.87e-06	4.56e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—RHOA—urinary bladder cancer	2.86e-06	4.56e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IL2—urinary bladder cancer	2.86e-06	4.55e-05	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.86e-06	4.55e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL2—urinary bladder cancer	2.85e-06	4.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TERT—urinary bladder cancer	2.84e-06	4.52e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PPARG—urinary bladder cancer	2.83e-06	4.51e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.83e-06	4.5e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EP300—urinary bladder cancer	2.81e-06	4.48e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.81e-06	4.47e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	2.8e-06	4.46e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—urinary bladder cancer	2.78e-06	4.42e-05	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—urinary bladder cancer	2.74e-06	4.37e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SRC—urinary bladder cancer	2.74e-06	4.36e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EP300—urinary bladder cancer	2.73e-06	4.35e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—CREBBP—urinary bladder cancer	2.72e-06	4.33e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—RRM2—urinary bladder cancer	2.71e-06	4.32e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.69e-06	4.28e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.68e-06	4.27e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—SRC—urinary bladder cancer	2.66e-06	4.23e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB2—urinary bladder cancer	2.65e-06	4.22e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	2.65e-06	4.22e-05	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—urinary bladder cancer	2.64e-06	4.19e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—TYMS—urinary bladder cancer	2.61e-06	4.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FGFR3—urinary bladder cancer	2.61e-06	4.15e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL2—urinary bladder cancer	2.6e-06	4.14e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—urinary bladder cancer	2.59e-06	4.13e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PPARG—urinary bladder cancer	2.58e-06	4.1e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.58e-06	4.1e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.58e-06	4.1e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—EP300—urinary bladder cancer	2.57e-06	4.08e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.56e-06	4.08e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.54e-06	4.04e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ESR1—urinary bladder cancer	2.53e-06	4.03e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ENO2—urinary bladder cancer	2.51e-06	4e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	2.51e-06	4e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.5e-06	3.98e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—SRC—urinary bladder cancer	2.5e-06	3.97e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—CREBBP—urinary bladder cancer	2.48e-06	3.94e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—urinary bladder cancer	2.47e-06	3.93e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.47e-06	3.93e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.46e-06	3.92e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—TYMS—urinary bladder cancer	2.46e-06	3.92e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CDKN1A—urinary bladder cancer	2.45e-06	3.91e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MYC—urinary bladder cancer	2.45e-06	3.9e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.45e-06	3.9e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—PTEN—urinary bladder cancer	2.45e-06	3.9e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	2.44e-06	3.88e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	2.43e-06	3.87e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	2.43e-06	3.87e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.43e-06	3.87e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.43e-06	3.86e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.42e-06	3.86e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTP1—urinary bladder cancer	2.41e-06	3.84e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.4e-06	3.82e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—urinary bladder cancer	2.4e-06	3.82e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.39e-06	3.8e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	2.39e-06	3.8e-05	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—urinary bladder cancer	2.36e-06	3.76e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.35e-06	3.74e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.34e-06	3.72e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—EP300—urinary bladder cancer	2.34e-06	3.72e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GPX1—urinary bladder cancer	2.33e-06	3.71e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—urinary bladder cancer	2.33e-06	3.71e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	2.29e-06	3.64e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.28e-06	3.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—SRC—urinary bladder cancer	2.27e-06	3.62e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—CDKN1A—urinary bladder cancer	2.27e-06	3.61e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—urinary bladder cancer	2.27e-06	3.61e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTEN—urinary bladder cancer	2.26e-06	3.6e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—TYMS—urinary bladder cancer	2.26e-06	3.59e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—TYMS—urinary bladder cancer	2.24e-06	3.57e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	2.23e-06	3.55e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	2.23e-06	3.55e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—urinary bladder cancer	2.23e-06	3.55e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GSTM1—urinary bladder cancer	2.22e-06	3.53e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—NCOR1—urinary bladder cancer	2.22e-06	3.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CREBBP—urinary bladder cancer	2.22e-06	3.53e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—urinary bladder cancer	2.2e-06	3.5e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF1—urinary bladder cancer	2.19e-06	3.49e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—EP300—urinary bladder cancer	2.16e-06	3.43e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	2.15e-06	3.42e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GPX1—urinary bladder cancer	2.14e-06	3.4e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GPX1—urinary bladder cancer	2.13e-06	3.38e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	2.12e-06	3.37e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	2.1e-06	3.34e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—SRC—urinary bladder cancer	2.1e-06	3.34e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.09e-06	3.33e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ERCC2—urinary bladder cancer	2.09e-06	3.32e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTEN—urinary bladder cancer	2.08e-06	3.32e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—urinary bladder cancer	2.07e-06	3.29e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—urinary bladder cancer	2.06e-06	3.28e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	2.03e-06	3.23e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.03e-06	3.22e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—urinary bladder cancer	2.01e-06	3.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—RHOA—urinary bladder cancer	2.01e-06	3.19e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.99e-06	3.17e-05	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—EP300—urinary bladder cancer	1.99e-06	3.16e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.97e-06	3.14e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.97e-06	3.13e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.96e-06	3.13e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MTHFR—urinary bladder cancer	1.96e-06	3.12e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.94e-06	3.09e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.94e-06	3.09e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTEN—urinary bladder cancer	1.94e-06	3.09e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.94e-06	3.09e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.94e-06	3.09e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—urinary bladder cancer	1.93e-06	3.07e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—urinary bladder cancer	1.88e-06	2.99e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.88e-06	2.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—MYC—urinary bladder cancer	1.88e-06	2.99e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—urinary bladder cancer	1.87e-06	2.98e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.86e-06	2.96e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—urinary bladder cancer	1.86e-06	2.96e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.85e-06	2.95e-05	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—EP300—urinary bladder cancer	1.85e-06	2.95e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.85e-06	2.94e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—urinary bladder cancer	1.84e-06	2.92e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.83e-06	2.92e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.83e-06	2.92e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.83e-06	2.91e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.77e-06	2.82e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.77e-06	2.81e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CXCL8—urinary bladder cancer	1.76e-06	2.8e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—urinary bladder cancer	1.76e-06	2.8e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.75e-06	2.79e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—urinary bladder cancer	1.75e-06	2.78e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PPARG—urinary bladder cancer	1.74e-06	2.78e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—urinary bladder cancer	1.74e-06	2.76e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.72e-06	2.74e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.72e-06	2.73e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.71e-06	2.73e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.69e-06	2.69e-05	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—EP300—urinary bladder cancer	1.69e-06	2.68e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL2—urinary bladder cancer	1.68e-06	2.68e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	1.68e-06	2.67e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CCND1—urinary bladder cancer	1.64e-06	2.61e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.63e-06	2.6e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.62e-06	2.58e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.6e-06	2.55e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—urinary bladder cancer	1.6e-06	2.54e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—urinary bladder cancer	1.59e-06	2.54e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PPARG—urinary bladder cancer	1.59e-06	2.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CDKN1A—urinary bladder cancer	1.59e-06	2.53e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTEN—urinary bladder cancer	1.58e-06	2.52e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.57e-06	2.5e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.56e-06	2.49e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.55e-06	2.47e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.55e-06	2.47e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.54e-06	2.45e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—CREBBP—urinary bladder cancer	1.53e-06	2.43e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—EP300—urinary bladder cancer	1.51e-06	2.4e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.49e-06	2.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—urinary bladder cancer	1.48e-06	2.35e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SRC—urinary bladder cancer	1.47e-06	2.34e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.46e-06	2.32e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.45e-06	2.31e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.39e-06	2.22e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	1.37e-06	2.18e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.37e-06	2.18e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.34e-06	2.13e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MYC—urinary bladder cancer	1.32e-06	2.09e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.31e-06	2.09e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.3e-06	2.07e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.27e-06	2.02e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.26e-06	2.01e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.26e-06	2e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—urinary bladder cancer	1.25e-06	1.99e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—urinary bladder cancer	1.22e-06	1.94e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.21e-06	1.93e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.21e-06	1.92e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.2e-06	1.91e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.2e-06	1.91e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTEN—urinary bladder cancer	1.2e-06	1.9e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.15e-06	1.83e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—EP300—urinary bladder cancer	1.14e-06	1.82e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.13e-06	1.79e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.11e-06	1.77e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.1e-06	1.75e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.1e-06	1.74e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTEN—urinary bladder cancer	1.09e-06	1.74e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—urinary bladder cancer	1.08e-06	1.72e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.07e-06	1.7e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.06e-06	1.68e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.05e-06	1.67e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—EP300—urinary bladder cancer	1.04e-06	1.66e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—urinary bladder cancer	1.03e-06	1.64e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.03e-06	1.64e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTEN—urinary bladder cancer	9.56e-07	1.52e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—EP300—urinary bladder cancer	9.12e-07	1.45e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTEN—urinary bladder cancer	9.01e-07	1.43e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	8.75e-07	1.39e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—EP300—urinary bladder cancer	8.59e-07	1.37e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	8.58e-07	1.37e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	8.25e-07	1.31e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTEN—urinary bladder cancer	7.63e-07	1.21e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—EP300—urinary bladder cancer	7.28e-07	1.16e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.75e-07	1.07e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.89e-07	9.37e-06	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.62e-07	8.94e-06	CbGpPWpGaD
